SRNE - Sorrento posts updated results from early-stage COVID-19 trial

Sorrento Therapeutics (SRNE) posts updated positive results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) for patients suffering from COVID-19-induced acute respiratory distress ((ARD)) or acute respiratory distress syndrome ((ARDS)).The study is a single arm, non-randomized early-stage study of the safety and preliminary efficacy of COVI-MSCs administered every other day for three infusions for a total of 1 x 106 cells/kg, with the main goal of evaluating the safety of intravenous infusion of allogeneic adipose MSC cells in patients with COVID-19-induced ARD or ARDS.All nine patients in the study with acute respiratory failure due to COVID-19 discharged from hospital within days after 3rd COVI-MSC infusion.The company also added that preparations were ongoing for initiating a Phase 2 placebo-controlled study.

For further details see:

Sorrento posts updated results from early-stage COVID-19 trial